congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
T-DXd
ESMO Breast 2024 | May 15-17, 2024
A health-related quality of life (QOL) analysis from DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) versus capecitabine (CAP) in patients with hormone receptor–positive (HR+), HER2-low metastatic breast cancer (mBC)
Oral
Dato-DXd
ESMO Breast 2024 | May 15-17, 2024
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in pretreated, inoperable/metastatic HR+/HER2– breast cancer: Additional safety analysis from TROPION-Breast01
Poster
T-DXd
ESMO Breast 2024 | May 15-17, 2024
Exploratory pooled safety analysis of trastuzumab deruxtecan (T-DXd) in patients with HER2+ or HER2-low unresectable and/or metastatic breast cancer in DESTINY-Breast trials
Poster
T-DXd
ESMO Breast 2024 | May 15-17, 2024
French real-world safety and effectiveness of trastuzumab deruxtecan (T-DXd) in the treatment of patients with HER2+ metastatic or unresectable breast cancer (m/u BC): First results of REALITY-01 ambispective study
Mini-Oral
T-DXd
ESMO Breast 2024 | May 15-17, 2024
Pooled analysis of trastuzumab deruxtecan (T-DXd) retreatment after recovery from grade 1 interstitial lung disease/pneumonitis (ILD)
Poster
T-DXd
ESMO Breast 2024 | May 15-17, 2024
PROVIDENCE: A prospective, non-interventional study examining real-world clinical and patient-reported outcome (PRO) data in patients (pts) with HER2-positive or HER2-low unresectable or metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)
Poster
T-DXd
ESMO Breast 2024 | May 15-17, 2024
Real-world treatment patterns in patients with HER2 positive unresectable or metastatic breast cancer: HER2 REAL study final analysis in Asia-Pacific (APAC) and Brazil
Poster
T-DXd
ESMO Breast 2024 | May 15-17, 2024
Safety, tolerability, and antitumor activity of T-DXd in patients with HER2-positive mBC and active brain metastases in DESTINY-Breast07
Mini-Oral
T-DXd
ESMO Breast 2024 | May 15-17, 2024
Trastuzumab deruxtecan vs treatment of physician’s choice in patients with HER2+ metastatic breast cancer previously treated with trastuzumab emtansine: Updated overall survival results of the randomized, phase 3 DESTINY-Breast02 study
Poster
Dato-DXd
ESMO Breast 2024 | May 15-17, 2024
TROPION-Breast04: A phase 3 study of neoadjuvant datopotamab deruxtecan (Dato-DXd) + durvalumab followed by adjuvant durvalumab vs standard of care in treatment-naïve early-stage triple negative and HR-low/HER2– breast cancer
Páginas:
1 2